NTRA:NGS-Natera Inc. (USD)

EQUITY | Diagnostics & Research | Nasdaq Global Select

Last Closing

USD 94.04

Change

+2.38 (+2.60)%

Market Cap

USD 0.67B

Volume

1.54M

Analyst Target

USD 56.20
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Natera Inc is a diagnostics company with proprietary molecular and bioinformatics technology that it is deploying to change the management of genetic disease.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-29 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

-7.59 (-1.38%)

USD 43.04B
ICLR ICON PLC

-5.97 (-1.86%)

USD 26.09B
ILMN Illumina Inc

-0.55 (-0.48%)

USD 18.41B
MEDP Medpace Holdings Inc

-12.60 (-3.10%)

USD 12.09B
EXAS EXACT Sciences Corporation

-1.39 (-2.61%)

USD 9.96B
RDNT RadNet Inc

-0.66 (-1.13%)

USD 4.19B
SHC Sotera Health Co

N/A

USD 3.13B
OLK Olink Holding AB ADR

-0.06 (-0.25%)

USD 2.90B
GH Guardant Health Inc

+0.49 (+1.90%)

USD 2.74B
NEOG Neogen Corporation

+0.11 (+0.83%)

USD 2.67B

ETFs Containing NTRA

GN0M:XETRA Global X Genomics & Biote.. 8.46 % 0.00 %

-0.04 (0.51%)

USD 7.05M
GNOG:LSE Global X Genomics & Biote.. 8.34 % 0.00 %

-0.03 (0.51%)

USD 6.47M
GNOM:SW Global X Genomics & Biote.. 7.23 % 0.00 %

N/A

USD 6.40M
EKG First Trust Nasdaq Lux Di.. 4.45 % 0.00 %

-0.01 (0.51%)

USD 2.41M
CURG:LSE VanEck Genomics and Healt.. 4.35 % 0.00 %

+0.08 (+0.51%)

USD 6.86M
CURE:XETRA VanEck Genomics and Healt.. 3.95 % 0.00 %

+0.11 (+0.51%)

USD 6.78M
PTH Invesco DWA Healthcare Mo.. 3.11 % 0.60 %

-0.25 (0.51%)

USD 0.14B
CDNA:CA CI Bio-Revolution ETF 2.87 % 0.00 %

+0.15 (+0.51%)

CAD 5.70M
BTEC Principal Healthcare Inno.. 2.74 % 0.42 %

-0.06 (0.51%)

USD 0.04B
WBIO:LSE WisdomTree BioRevolution .. 2.24 % 0.00 %

-11.00 (0.51%)

USD 0.45M
WDNA:LSE WisdomTree BioRevolution .. 2.24 % 0.00 %

-0.13 (0.51%)

USD 2.81M
WDNA 2.13 % 0.00 %

N/A

N/A
WRNA:XETRA WisdomTree BioRevolution .. 2.10 % 0.00 %

-0.08 (0.51%)

USD 2.77M
DOCG:LSE L&G Healthcare Breakthrou.. 2.01 % 0.00 %

+3.45 (+0.51%)

USD 0.07B
DOCT:LSE L&G Healthcare Breakthrou.. 2.01 % 0.00 %

+0.05 (+0.51%)

USD 0.07B
XMLH:F Legal & General Ucits Etf.. 1.81 % 0.00 %

+0.03 (+0.51%)

USD 0.07B
DOCT:SW L&G Healthcare Breakthrou.. 1.81 % 0.00 %

+0.02 (+0.51%)

USD 0.07B
WELP:LSE HAN-GINS Indxx Healthcare.. 1.67 % 0.00 %

-1.75 (0.51%)

USD 0.02B
WELL:PA HAN-GINS Indxx Healthcare.. 1.52 % 0.00 %

-0.03 (0.51%)

N/A
WELL:SW HAN-GINS Indxx Healthcare.. 1.52 % 0.00 %

+0.08 (+0.51%)

N/A
CURE:AU ETFS S&P Biotech ETF 1.18 % 0.00 %

+0.59 (+0.51%)

USD 0.04B
JKK iShares Morningstar Small.. 0.59 % 0.30 %

N/A

USD 0.55B
JKJ iShares Morningstar Small.. 0.30 % 0.25 %

N/A

USD 0.22B
FHH:CA First Trust AlphaDEX US H.. 0.00 % 0.77 %

N/A

CAD 0.01B
FXH First Trust Health Care A.. 0.00 % 0.63 %

-0.43 (0.51%)

USD 1.25B
LABU Direxion Daily S&P Biotec.. 0.00 % 1.14 %

-0.52 (0.51%)

USD 1.04B
GNOM Global X Genomics & Biote.. 0.00 % 0.00 %

N/A

USD 0.10B
HTEC Robo Global® Healthcare .. 0.00 % 0.00 %

+0.04 (+0.51%)

USD 0.06B
SCHA Schwab U.S. Small-Cap ETF 0.00 % 0.05 %

-0.34 (0.51%)

USD 16.65B
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

-0.02 (0.51%)

USD 6.80B
DRDR:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

-1.13 (0.51%)

USD 1.07B
WELL:LSE Hanetf Icav - Han-Gins He.. 0.00 % 0.00 %

-0.01 (0.51%)

USD 0.02B
IS0R:F iShares High Yield Corpor.. 0.00 % 0.00 %

-2.68 (0.51%)

USD 3.29B
2B78:XETRA iShares Healthcare Innova.. 0.00 % 0.00 %

-0.01 (0.51%)

USD 1.14B
IS0R:XETRA iShares High Yield Corpor.. 0.00 % 0.00 %

-2.75 (0.51%)

USD 2.71B
W311:XETRA HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

-0.02 (0.51%)

USD 0.02B
XMLH:XETRA L&G Healthcare Breakthrou.. 0.00 % 0.00 %

+0.05 (+0.51%)

USD 0.07B
FRTY Alger Mid Cap 40 ETF 0.00 % 0.00 %

-0.04 (0.51%)

USD 0.03B
FHH-F:CA First Trust AlphaDEX U.S... 0.00 % 0.00 %

+0.26 (+0.51%)

CAD 0.01B
ISCG iShares Morningstar Small.. 0.00 % 0.00 %

-0.57 (0.51%)

USD 0.55B
ATFV Alger 35 ETF 0.00 % 0.00 %

-0.07 (0.51%)

USD 0.02B
2B78:F iShares Healthcare Innova.. 0.00 % 0.00 %

-0.01 (0.51%)

N/A
W311:F HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

-0.02 (0.51%)

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 50.13% 95% A 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 50.13% 95% A 92% A
Trailing 12 Months  
Capital Gain 79.19% 93% A 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 79.19% 93% A 92% A
Trailing 5 Years  
Capital Gain 399.95% 97% N/A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 399.95% 97% N/A 96% N/A
Average Annual (5 Year Horizon)  
Capital Gain 44.81% 84% B 90% A-
Dividend Return 44.81% 84% B 90% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 87.17% 34% F 18% F
Risk Adjusted Return 51.40% 88% B+ 81% B-
Market Capitalization 0.67B 92% A 93% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 14.90 10% 7%
Price / Cash Flow Ratio -45.37 94% 93%
Price/Free Cash Flow Ratio -27.58 92% 92%
Management Effectiveness  
Return on Equity -59.11% 46% 28%
Return on Invested Capital -40.41% 50% 26%
Return on Assets -19.67% 45% 25%
Debt to Equity Ratio 36.97% 52% 48%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector